No Data
No Data
Wells Fargo Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $78
Wells Fargo analyst Mohit Bansal maintains $Gilead Sciences(GILD.US)$ with a hold rating, and maintains the target price at $78.According to TipRanks data, the analyst has a success rate of 58.3% and
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $80
BMO Capital analyst Evan Seigerman maintains $Gilead Sciences(GILD.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 47.2% and
Analysts' Top Healthcare Picks: Scholar Rock Holding (SRRK), Gilead Sciences (GILD)
Gilead Sciences (GILD) Gets a Hold From Wells Fargo
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.07% on an annualized basis producing an average annual return of 11.12%. Currently, Gilead Sciences has a market c
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.